FTC’s M&A crackdown; NASH drug gets thumbs down; FDA OKs topical gene therapy; Company exits frustrate rare disease families; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
June is going to be busy with conferences, and we have lined up a full slate of panels at both ASCO (virtual) and BIO (mix of virtual and live in Boston). Be sure to check them out.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.